Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1976 Mar;220(1):72-85.

Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug

  • PMID: 952578

Intravenous pharmacokinetic profile in rats of etomidate, a short-acting hypnotic drug

P J Lewi et al. Arch Int Pharmacodyn Ther. 1976 Mar.

Abstract

Etomidate is a novel short-acting drug, whose pharmacokinetic profile was studied in 14 organs and tissues after i.v. administration to rats. Four dose levels, ranging from 224 to 1800 mug, were assayed between 1.75 and 112 min after administration. A three-compartment open linear model has been fitted to the plasma concentrations, assuming a central, peripheral and deep compartment. The fast component of the plasma curve, has a half-life of 1.19 min. Brain tissue rapidly enters in equilibrium with plasma and shows the highest concentration. Muscle, subcutaneous fat and possibly skin and connective tissues contribute most to the total amount of drug in the body. Many tissues are heterogeneous and exhibit combinations of central, peripheral and deep compartments. Elimination of etomidate occurs by ester-hydrolysis in plasma and in the liver with approximately equal rate constants. Metabolization of etomidate in the liver is a capacity-limited Michaelis-Menten process.

PubMed Disclaimer